Organ for breathing air
POPULARITY
Categories
419 episodes with pulmonary
117 episodes with pulmonary
79 episodes with pulmonary
57 episodes with pulmonary
34 episodes with pulmonary
37 episodes with pulmonary
56 episodes with pulmonary
32 episodes with pulmonary
32 episodes with pulmonary
20 episodes with pulmonary
25 episodes with pulmonary
15 episodes with pulmonary
13 episodes with pulmonary
14 episodes with pulmonary
11 episodes with pulmonary
16 episodes with pulmonary
26 episodes with pulmonary
15 episodes with pulmonary
6 episodes with pulmonary
11 episodes with pulmonary
10 episodes with pulmonary
9 episodes with pulmonary
10 episodes with pulmonary
8 episodes with pulmonary
8 episodes with pulmonary
6 episodes with pulmonary
6 episodes with pulmonary
13 episodes with pulmonary
4 episodes with pulmonary
9 episodes with pulmonary
4 episodes with pulmonary
7 episodes with pulmonary
10 episodes with pulmonary
4 episodes with pulmonary
5 episodes with pulmonary
4 episodes with pulmonary
10 episodes with pulmonary
7 episodes with pulmonary
11 episodes with pulmonary
10 episodes with pulmonary
4 episodes with pulmonary
3 episodes with pulmonary
4 episodes with pulmonary
5 episodes with pulmonary
5 episodes with pulmonary
4 episodes with pulmonary
4 episodes with pulmonary
4 episodes with pulmonary
4 episodes with pulmonary
7 episodes with pulmonary
3 episodes with pulmonary
7 episodes with pulmonary
4 episodes with pulmonary
6 episodes with pulmonary
Dr. Tijana Milinic and Lia Barros, DNP, from the University of Washington take a deep dive into the world of pulmonary arterial hypertension (PAH) clinical trials and discuss why diversity and inclusion matter. They explore the hidden biases in medical research and the real-world consequences of exclusion. Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com Like, Subscribe and Follow us: www.phawarepodcast.com. @uwepidemiology #phawareMD
In this episode of 'Patients at Risk,' Angie Pereira shares the heartbreaking story of losing her father due to a misdiagnosed pulmonary embolism by a nurse practitioner in an after-hours clinic. Despite her father's presenting symptoms of shortness of breath and leg pain, strong family history of blood clots, and normal lung exam, the nurse practitioner diagnosed him with pneumonia, leading to his untimely death the next day. Angie emphasizes the need for proper physician oversight and questions the push for independent practice for nurse practitioners. The discussion extends to issues of legislative accountability, corporate healthcare's role in potentially compromising patient care, and the necessity for patients to advocate for themselves to ensure high-quality medical care. Angie's story highlights the broader implications of inadequate training and supervision in healthcare, especially affecting rural communities.PhysiciansForPatientProtection.org
Two cases of extra-pulmonary tb encountered in LMICs are presented Speaker(s): Scott Armistead Session webpage: https://www.medicalmissions.com/events/gmhc-2024/sessions/case-studies-in-extra-pulmonary-tb
Dr. Lana Melendres-Groves dives into her research on racial and ethnic disparities in PAH treatment. From differences in medication access to the role of social determinants of health, she explores how systemic barriers impact care and what steps can be taken to ensure equity and inclusivity in PAH management. Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com Like, Subscribe and Follow us: www.phawarepodcast.com. @UNMHSC #phawareMD
On this episode of the ATS Breathe Easy podcast, meet the newly-elected ATS President, Raed Dweik, MD, MBA, ATSF. Host Amy Attaway, MD, MS, talks with Dr. Dweik on his vision for the ATS, and what he is most excited for in the fields of respiratory health, critical care, and how the ATS is braced to help members face ongoing challenges. Did you miss the ATS 2025 International Conference? Or were you unable to attend some key sessions? Go to conference.thoracic.org/program/conference-highlights/ to purchase your ATS Conference Highlight Package. Be sure to check out the Out of the Blue podcast from the American Journal of Respiratory and Critical Care Medicine, which takes you out of the pages of the Blue Journal and into the minds of the most brilliant researchers in the fields of respiratory, critical care, and sleep medicine. Tune in wherever you listen to podcasts!
We have a powerful conversation about dedication, innovation, and impact in the cystic fibrosis community in this podcast. I'm joined by two incredible guests from MVW Nutritionals: Mike Walters and Jason Vandiver.Mike Walters is a true pioneer in pharmaceutical business and innovation, with nearly four decades of experience. He began his career at Johnson & Johnson, where he spent 14 years in leadership roles across sales, marketing, and management development. In 1996, Mike launched his first company to help organizations navigate product commercialization in the U.S. Since then, his work in the CF space has been nothing short of groundbreaking. He founded and led Source CF, MVW Nutritionals, and CF Global Services, playing a key role in bringing many standard-of-care treatments to market. A Vanderbilt graduate with degrees in Biochemistry and Chemistry, Mike brings both scientific insight and a deep commitment to rare disease care.Joining him is Jason Vandiver, Chief Operating Officer of MVW Nutritionals. A proud Alabama native, Jason earned his degree in Finance from the University of Alabama at Birmingham and spent 16 years in banking before joining MVW during a time of rapid growth. He now helps lead the multimillion-dollar, family-owned company that's become a global leader in nutritional products for patients with CF and non-CF EPI.In this episode, Mike and Jason share their personal stories, the importance of strong partnerships, and the real challenges patients and families are facing—especially as funding landscapes continue to shift. We explore the power of empathy, the strength of community support, and why transparency in nonprofit operations matters now more than ever.It's a conversation about hope, action, and what's ahead as we work together to support those who need us most. Please like, subscribe, and comment on our podcasts!Please consider making a donation: https://thebonnellfoundation.org/donate/The Bonnell Foundation website:https://thebonnellfoundation.orgEmail us at: thebonnellfoundation@gmail.com Watch our podcasts on YouTube: https://www.youtube.com/@laurabonnell1136/featuredThanks to our sponsors:Vertex: https://www.vrtx.comViatris: https://www.viatris.com/en
Dr. Roham Zamanian, discusses the concept of "disease modification" in the treatment of pulmonary hypertension. He describes how this idea emerged from discussions with colleagues about the future of pulmonary hypertension therapies, and the potential for treatments to impact the underlying disease process beyond just reducing pulmonary artery pressures. This Special Edition Episode Sponsored by: Johnson & Johnson Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Follow us on social @phaware Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com #phawareMD @PHatStanford @docroham @JNJInnovMed
On this edition of the ATS Breathe Easy: The Latest, host Patti Tripathi and Foundation for Sarcoidosis Research President and CEO Mary McGowan discuss sarcoidosis research and the Champions for Change movement to encourage companies to allow employees to use paid time off to enroll in clinical trials. To learn more, go to ignorenomore.org. Did you miss the ATS 2025 International Conference? Or were you unable to attend some key sessions? Go to conference.thoracic.org/program/conference-highlights/ to purchase your ATS Conference Highlight Package. Be sure to check out the Out of the Blue podcast from the American Journal of Respiratory and Critical Care Medicine, which takes you out of the pages of the Blue Journal and into the minds of the most brilliant researchers in the fields of respiratory, critical care, and sleep medicine. Tune in wherever you listen to podcasts!
Justin Aunger, PhD, and Kay Por Yip MBChB, PhD, join CHEST® Journal Podcast Moderator, Gretchen Winter, MD, to discuss their research into interventions for improving adherence to clinical guidelines for the management and follow-up of pulmonary nodules. DOI: 10.1016/j.chest.2025.02.031 Disclaimer: The purpose of this activity is to expand the reach of CHEST content through awareness, critique, and discussion. All articles have undergone peer review for methodologic rigor and audience relevance. Any views asserted are those of the speakers and are not endorsed by CHEST. Listeners should be aware that speakers' opinions may vary and are advised to read the full corresponding journal article(s) for complete context. This content should not be used as a basis for medical advice or treatment, nor should it substitute the judgment used by clinicians in the practice of evidence-based medicine.
Video: https://mehlmanmedical.com/hy-usmle-q-1411-pulmonaryIG: https://www.instagram.com/mehlman_medical/Telegram: https://mehlmanmedical.com/subscribe/FB: https://www.facebook.com/mehlmanmedical
In this podcast, Series 4, Chapter 3, Dr. Barsuk interviews Dr. Brian Garibaldi, Professor of Medicine in the Division of Pulmonary and Critical Care at Northwestern Feinberg School of Medicine. Dr. Garibaldi also serves as the Charles Horace Mayo Professor and the Director of the Northwestern Center for Bedside Medicine. Drs. Barsuk and Garibaldi discuss training in bedside medicine using simulation.
Substack is where I discovered Dr. MeiLan Han! I was browsing through and was pleasantly surprised to read an article, and learn that she wrote a book called, Breathing Lessons. And to top it off, she's from my home state of Michigan. I also learned the Dr. Han's book was “a passion project during the pandemic.”I'm delighted to share a conversation with Dr. MeiLan Han, one of the country's most respected voices in lung health and a tireless advocate for people living with chronic respiratory conditions.Dr. Han is a Professor of Medicine and Chief of Pulmonary and Critical Care at University of Michigan Health. She's not only cared for patients at the bedside but has devoted her career to understanding lung disease at its roots, with a special focus on chronic obstructive pulmonary disease (COPD), a condition that remains widely under-recognized and underfunded. Through her research, Dr. Han is helping to uncover how diseases like COPD affect the lungs in different ways, with the goal of making treatment more precise, more effective, and more personalized.Her journey began at the University of Washington and continued through specialized training at the University of Michigan, where she also earned a Master's degree in Biostatistics and Clinical Study Design. Today, she leads research funded by the National Institutes of Health (NIH), serves on national advisory boards for the COPD Foundation and the American Lung Association, and contributes to global guidelines that shape how lung disease is diagnosed and treated.Dr. Han also serves as Deputy Editor of the American Journal of Respiratory and Critical Care Medicine, helping to guide the direction of clinical practice and research in pulmonary medicine.If you or someone you love is living with a chronic lung condition, Dr. Han's insight is not only encouraging, it's essential. I'm so grateful to bring her voice to this platform. How many breathes do we take in a lifetime? It's fascinating to discuss and you'll hear the answer in our podcast.Lung health, do you think about it?To get her book: https://www.amazon.com/Breathing-Lessons-Doctors-Guide-Health-ebook/dp/B08X2ZFGNZ/ref=tmm_kin_swatch_0 Please like, subscribe, and comment on our podcasts!Please consider making a donation: https://thebonnellfoundation.org/donate/The Bonnell Foundation website:https://thebonnellfoundation.orgEmail us at: thebonnellfoundation@gmail.com Watch our podcasts on YouTube: https://www.youtube.com/@laurabonnell1136/featuredThanks to our sponsors:Vertex: https://www.vrtx.comViatris: https://www.viatris.com/en
Dr. Yogesh Saini speaks with Dr. Michael Yaeger and Dr. Kymberly Gowdy about their article, Docosahexaenoic Acid and Its Metabolites Protects Against Ozone-induced Pulmonary Inflammation.
Hall Skaara, representing PHA Europe, brought the patient perspective to the forefront at the World Symposium on Pulmonary Hypertension, joining other members of Task Force 1. PHA Europe was well-represented with delegates including Eva Otter, Monika Tschida, Natalia Maeva, Tadeja Ravnik, and Nina Kobler. This prestigious event gathered over 1,500 of the brightest minds in the field of pulmonary hypertension, offering a unique opportunity for patients and professionals to collaborate and share insights, as well as for patient associations to network. This Special Edition Episode Sponsored by: Johnson & Johnson Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Follow us on social @phaware Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com @EuropePHA @Hall_Skaara @JNJInnovMed
In this podcast, Anne E. O'Donnell, MD, discusses the latest advances and treatment strategies for patients with non–cystic fibrosis bronchiectasis (NCFBE), including:Airway clearance as a foundation of NCFBE managementStrategies to address inflammation and exacerbationsEmerging therapies in clinical developmentHow to individualize treatment to NCFBE phenotypes and endotypesPresenterAnne E. O'Donnell, MDProfessor of MedicineThe Nehemiah and Naomi Cohen Chair in Pulmonology Disease ResearchChief, Division of Pulmonary, Critical Care and Sleep MedicineGeorgetown University Medical CenterWashington, DCProgram page:https://bit.ly/4mZbYsm
Why Pulmonary Hypertension Isn't Just a Lung ProblemCardiologist Dr. Lisa Mielniczuk from the Mayo Clinic pulls back the curtain on one of the most common — yet misunderstood — forms of pulmonary hypertension: the kind caused by left heart disease. In this episode, she explains why it's time we stop thinking of PH as a rare condition. Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Follow us on social @phaware Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com @phacanada #phawareMD @mayoclinic @teamphhope
Beyond the Clinical Trial: What Real-World Data Means for You Think only people in clinical trials help advance medicine? Think again. Dr. Jason Weatherald explains how your everyday clinic visits — from walk tests to how you feel — can help shape the future of pulmonary hypertension treatment. Learn what "real-world evidence" is and why your story matters more than you think. Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Follow us on social @phaware Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com @phacanada #phawareMD @teamphhope @AlbertaPHdoc @UAlberta
In this episode, Julie, Stephanie, and Suzanne answer the listeners question of how to differentiate between signs, symptoms, and diagnosis of an AFE v. a PEThe experts at Clinical Concepts in Obstetrics pool their decades of experience caring for critically ill pregnant women to discuss the challenges encountered in caring for these vulnerable women. Dr Stephanie Martin is the Medical Director for Clinical Concepts in Obstetrics and a Maternal Fetal Medicine specialist with expertise in critical care obstetrics. Suzanne McMurtry Baird, DNP, RN is the Nursing Director for Clinical Concepts in Obstetrics with many years of experience caring for critically ill pregnant women. Julie Arafeh, RN, MS is the Simulation Director for Clinical Concepts in Obstetrics and a leading expert in simulation.Critical Care Obstetrics Academy: https://www.clinicalconceptsinob.com/Follow us: Instagram: https://www.instagram.com/criticalcareob/Dr Martin's LinkedIn: http://linkedin.com/in/stephanie-martin-65b07112aCCOB LinkedIn: https://www.linkedin.com/company/clinical-concepts-in-obstetrics/Twitter/X: https://twitter.com/OBCriticalCareCCOB Facebook: https://www.facebook.com/clinicalconceptsinobstetricsDr Ma...
BUFFALO, NY – June 9, 2025 – A new #research paper was #published in Volume 16 of Oncotarget on May 20, 2025, titled “Cigarette smoke and decreased DNA repair by Xeroderma Pigmentosum Group C use a double hit mechanism for epithelial cell lung carcinogenesis.” In this study, led by first author Nawar Al Nasralla and corresponding author Catherine R. Sears, from the Division of Pulmonary, Critical Care, Sleep and Occupational Medicine, Indianapolis and the Richard L. Roudebush Veterans Affairs Medical Center, researchers investigated how cigarette smoke and reduced DNA repair capacity contribute together to the development of lung cancer. They found that when a critical DNA repair protein called XPC is decreased and lung cells are exposed to cigarette smoke, the combination causes extensive damage and significantly increases cancer risk. Non-small cell lung cancer (NSCLC) develops through both genetic and environmental factors. This study focused on how cigarette smoke affects the body's natural ability to repair DNA. The researchers studied the role of XPC, a protein essential for recognizing and repairing harmful DNA changes caused by tobacco smoke. They found that low levels of XPC — commonly seen in lung cancer patients — made lung cells less capable of repairing DNA. This made the cells unstable and more likely to become cancerous. These changes were most pronounced in normal lung cells, suggesting that the earliest stages of disease occur before cancer is even detected. The findings support a “double hit” model, where both cigarette smoke and reduced DNA repair work together to drive cancer development. In laboratory experiments, normal lung cells with low XPC levels showed more damage and cell death after cigarette smoke exposure. By contrast, lung cancer cells were more resistant to smoke damage, even when XPC was low, indicating that critical changes had likely occurred earlier in the disease process. “Our study suggests that cigarette smoke exposure leads to decreased XPC mRNA expression, exacerbates total and oxidative DNA damage, hinders NER, and may contribute to lung cancer development.” The study also showed that DNA repair ability declined significantly in healthy cells after smoke exposure, but this effect was not seen in cancer cells. In addition, the researchers confirmed that XPC gene activity was lower in actual lung tumor tissue compared to nearby healthy lung tissue. This pattern was consistent across both adenocarcinoma and squamous cell carcinoma, the two main types of NSCLC. These results add to our understanding of how lung cancer begins at the molecular level. By showing how cigarette smoke and reduced DNA repair combine to create genetic instability, the research points toward new strategies for prevention. A better understanding of XPC's role could help identify high-risk individuals and inform future efforts to stop lung cancer before it begins. DOI - https://doi.org/10.18632/oncotarget.28724 Correspondence to - Catherine R. Sears - crufatto@iu.edu Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28724 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, DNA repair, DNA damage, lung adenocarcinoma, squamous cell carcinoma, Xeroderma Pigmentosum Group C (XPC) To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM
This episode originally aired on October 26th, 2023. Dr. Stephanie Maximous chats with Dr. Diana Kelm about her article, "Build It and They Shall Come: Medical Education Communities of Practice."
Host: Darryl S. Chutka, M.D. Guest: Robert L. Scott, M.D., Ph.D. Pulmonary hypertension is an important medical condition and often underrecognized in primary care. It has a variety of causes, and its most common presenting symptom is dyspnea. As primary care clinicians, we often see patients with symptoms of dyspnea and pulmonary hypertension is not a health problem we commonly encounter. Yet, early recognition and diagnosis is important and has major implications for patient outcomes. What are some clues that a patient might have pulmonary hypertension? What are its most common causes and what are the potential complications if it goes unrecognized? These are some of the questions I'll be asking my guest, Robert L. Scott, M.D., Ph.D., from the Department of Cardiovascular Medicine at the Arizona campus of the Mayo Clinic as we discuss “Pulmonary Hypertension”. ** Course link-- https://ce.mayo.edu/pulmonary-medicine/content/mayo-clinic-pulmonary-hypertension-symposium-2025 **Seats are limited, so visit our website to register now! Connect with us and learn more here: https://ce.mayo.edu/online-education/content/mayo-clinic-podcasts
Dr. Rodolfo Estrada, is a seasoned pulmonologists currently at UT Health San Antonio with significant experience in the management of patients with different forms of pulmonary hypertension. In this episode, Dr. Estrada will discuss the technology and clinical development behind YUTREPIA™ (treprostinil) inhalation powder and why it might be a good option for some PAH and PH-ILD patients. This Special Edition episode is sponsored by Liquidia. Please see the Important Safety Information following this podcast. The Prescribing Information and Instructions for Use for YUTREPIA (treprostinil) inhalation powder are available at YUTREPIA.com. YUTREPIA is approved for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) and pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve the ability to exercise. Please see the Important Safety Information in the show notes. The Prescribing Information and Instructions for Use for YUTREPIA are available at YUTREPIA.com. Learn more about the INSPIRE study. Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com Like, Subscribe and Follow us: www.phawarepodcast.com. #phawareMD #PHILD @Liquidia_Corp @REstradaMD @UTHealthSA IMPORTANT SAFETY INFORMATION Before you take YUTREPIA, tell your healthcare provider about all of your medical conditions, including if you: Have low blood pressure Have or have had bleeding problems Have asthma or chronic obstructive pulmonary disease (COPD) Are pregnant or plan to become pregnant. It is not known if this product will harm your unborn baby Are breastfeeding or plan to breastfeed. It is not known if this product passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby during treatment Tell your healthcare provider about all of the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. YUTREPIA and other medicines may affect each other. Especially tell your healthcare provider if you take: Medicines used to treat high blood pressure or heart disease Medicines that decrease blood clotting (anticoagulants) Water pills (diuretics) Gemfibrozil (Lopid®) or rifampin (Rimactane®, Rifadin®, Rifamate®, Rifater®) What are the possible side effects of YUTREPIA? This product can cause serious side effects, including: Low blood pressure (symptomatic hypotension). If you have low blood pressure, this product may lower your blood pressure more. Bleeding problems. This product may increase the risk of bleeding, especially in people who take blood thinners (anticoagulants). The most common side effects of YUTREPIA are cough, headache, throat irritation and pain, nausea, reddening of the face and neck (flushing), fainting or loss of consciousness, dizziness, diarrhea, and shortness of breath. Like other inhaled prostaglandins, you may have trouble breathing after taking YUTREPIA because it may cause the muscles around your airway to tighten (bronchospasm). These are not all the possible side effects. Call your doctor for medical advice about side effects or if you have trouble breathing. You may report side effects to the FDA at www.fda.gov/MedWatch or call 1–800-FDA-1088. The risk information provided here is not comprehensive. To learn more about YUTREPIA, talk with your healthcare provider. Please see Full Prescribing Information for YUTREPIA and Instructions for Use. For additional information, call 1–888–393–5732.
This episode begins our series on "What you may have missed at ATS 2025."We produce over 450 million tons of plastics each year, the vast majority of which has accumulated in the environment. Increasing evidence suggests that microplastics can accumulate in a number of different organs such as the brain, but what of the lungs? In this episode, Adam Soloff, PhD (self-described "Lorax of the Thorax"), associate professor, UPMC Hillman Cancer Center, walks us through his research to find out what these ever-present microplastics do to the lungs and the pulmonary immune system in particular. Spoiler alert: once inhaled, microplastics pass through the lung seeding many tissues of the body including the heart, brain, gut, liver, and spleen. "We found it everywhere we looked," said Dr. Soloff whose team's work begins to shed light on how microplastics damage lung immunity and may predispose us to lung disease in the future.4:16 What is a microplastic?6:19 Where is the most established evidence of how microplastics affects our health?
Decoding Pulmonary Hypertension: Echo and Cath Insights for Pulmonologists. Dr. Marc Simon shares his expertise on diagnosing pulmonary hypertension, emphasizing echocardiographic markers, right heart catheterization pitfalls, and risk stratification with the H2FPEF score. His insights help clinicians refine their diagnostic approach for better patient outcomes. This Special Edition episode is sponsored by Liquidia. View PDF Slides here. Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com Like, Subscribe and Follow us: www.phawarepodcast.com. #phawareMD #PHILD @Liquidia_Corp @UCSFCardiology @MarcSimonMD @CalThoracic
Live from Mix and Mingle Education Day: A Powerful Conversation with CaregiversIn this deeply moving live episode recorded at the Mix and Mingle Education Day, we brought together a powerful group of caregivers—grandparents, parents, stepparents, dads, and friends—for a heartfelt discussion about the emotional journey of caring for a loved one with cystic fibrosis.What started as a simple idea to gather voices turned into our most beautiful and emotional podcast yet. There were tears, laughter, and unforgettable stories. We were honored to be joined by a Grief Counselor who helped guide us through the complex feelings that surfaced during our conversation.This episode is a raw, real, and uplifting tribute to the strength, vulnerability, and love that caregivers bring to their roles every single day.Join us for a conversation that honors the heart of caregiving and the power of community.You'll hear from:(00:00:00) Laura Bonnell - Host - (Egypt, Foundation programs, legislation)(00:16:49) Lois Teicher - CF Grandmother (Laura's Mom) (00:19:05) Natalie Wicks Lois's partner(00:21:36) Julie Weatherhead - Grief Doula(00:28:45) Sharon Tischio - CF Mom(00:33:08) Cambria Whitaker - CF Mom in a queer/transgender relationship(00:38:55) Theresa Dagget, MSU Clinic, Respiratory Therapist, CF coordinator(00:49:00 ) Dorothy Stratford,CF Family Caregiver(00:52:15) Jillian Rogers Smith, 33 year old CF Patient and Dad, Bill Rogers (01:01:40) CF Mom to 6 year old daughter Louisa(01:07:28) Wendi Tague (Nurse Coordinator) and Claire Haglund (Social Worker) Present but not on the microphone were Joe Bonnell (Laura's husband), Jeannette Bovensie (Dorothy's Mom) and Dani Nettleton and daughter.Claire Haglund: CHaglund@dmc.orgWendi Tague: wtague@dmc.orgLois Teicher (Laura's Mom): Loisteicher@yahoo.comNatalie Wicks: Piccolo35@gmail.comTheresa Daggett: daggett3@msu.eduCambria Whittaker: cambriawhitta@gmail.comDorothy Straford: dstrat701@gmail.comSharon Tischio: stischio@comcast.netJamie Rudnycky: jamie.rudnycky@gmail.comJulie Weatherhead: weathervanecounseling@gmail.comJillian Smith, Jillian's Jay Walkers: jill@jilliansjaywalkers.org And Jillian's Dad, Bill Rogers Please like, subscribe, and comment on our podcasts!Please consider making a donation: https://thebonnellfoundation.org/donate/The Bonnell Foundation website:https://thebonnellfoundation.orgEmail us at: thebonnellfoundation@gmail.com Watch our podcasts on YouTube: https://www.youtube.com/@laurabonnell1136/featuredThanks to our sponsors:Vertex: https://www.vrtx.comViatris: https://www.viatris.com/en
You're doing everything right. You're on hormones, you've cut the caffeine, maybe you've even bought one of those expensive sleep trackers. So why are you still waking up at 3am, wired and restless?In this episode, I sit down with Dr. Andrea Matsumura—board-certified sleep physician and women's health specialist—to finally unpack why sleep is such a persistent struggle for women, especially during perimenopause and menopause. Andrea breaks down the biological, psychological, and cultural reasons why women are conditioned to expect poor sleep—and why it doesn't have to be that way.We talk melatonin myths (the dose matters), the silent epidemic of undiagnosed sleep apnea in women, and why most wearables are only telling part of the story. Andrea also explains why cannabis, supplements, and even hormone therapy may help—but won't fix the root cause for many women.Plus, we get into the real reason cognitive behavioral therapy for insomnia (CBT-I) actually works—if you're willing to do the work—and how the entire medical system is failing women by ignoring gender-specific data in sleep studies and diagnostics.If you're tired of being tired and want real, practical answers—not just another supplement or influencer sleep hack—this conversation is for you.HighlightsWhy hormone therapy helps some women sleep—but not all.How sleep apnea presents differently in women and often goes undiagnosed.The truth about melatonin: why most people take the wrong dose at the wrong time.Cannabis and sleep: what the research really shows.Why CBT-I is the gold standard for insomnia (and why apps alone aren't enough).Do you like what you heard? Don't forget to subscribe, like, and leave a comment on Apple Podcasts your support helps us reach more listeners who deserve better answers.Guest Bio:Dr. Andrea Matsumura MD MS FACP FAASM is a board certified sleep specialist and menopause expert, event and corporate speaker, group facilitator, co-founder of the Portland Menopause Collective, and creator of the Sleep Goddess MD D.R.E.A.M. Sleep Method™ and Sleep Goddess Archetype™.Dr. Matsumura attended medical school at The University of Texas Health Science Center in San Antonio. She moved to Portland, Oregon for her residency in Internal Medicine and was an Internal Medicine Physician with Northwest Permanente for 13 years before entering her fellowship in Sleep Medicine. She attended Oregon Health and Science University as a fellow in Sleep Medicine. She became a partner at The Oregon Clinic in Pulmonary, Critical Care, and Sleep Medicine after completing her fellowship. During her tenure there she focused on women's health and became a sought-after expert on women and sleep. She is currently the Medical Director of primary care services and medical home development for Cascadia Health in Portland, Oregon and has plans to develop sleep services.Get in Touch with Dr. MatsumuraWebsiteInstagramGet in Touch with Dr. Rahman:WebsiteInstagramYoutube
Video: https://mehlmanmedical.com/hy-usmle-q-1380-pulmonaryIG: https://www.instagram.com/mehlman_medical/Telegram: https://mehlmanmedical.com/subscribe/FB: https://www.facebook.com/mehlmanmedical
Video: https://mehlmanmedical.com/hy-usmle-q-1378-pulmonaryIG: https://www.instagram.com/mehlman_medical/Telegram: https://mehlmanmedical.com/subscribe/FB: https://www.facebook.com/mehlmanmedical
Dr. Jean Elwing, a leading expert in pulmonary hypertension, discusses groundbreaking advancements in treating pulmonary hypertension associated with interstitial lung disease (PH-ILD). For years, patients with this condition had limited treatment options beyond oxygen therapy and symptom management. However, recent studies have introduced new hope, showing improved patient outcomes and quality of life. Dr. Elwing emphasizes the importance of early diagnosis, ongoing research, and clinical trial participation in pushing the field forward. This Special Edition episode is sponsored by Gossamer Bio and Pulmovant. Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com Like, Subscribe and Follow us: www.phawarepodcast.com. #phawareMD #PHILD @uc_health @ElwingJean @GossamerBio #Pulmovant @accpchest #PHOCUSstudy #PROSERAstudy
Cystic Fibrosis and obesity? Until recently this has not been a topic of conversation for the CF community. The reason for obesity in the CF community is better health and longer lives, so the concern is now a reality. University of Michigan CF doctor, Carey Lumeng is researching the issue. As he says in this podcast, researchers have a lot to learn about the connection between better health in CF and obesity. We also talk about The Bonnell Foundation fellowship program. A few years ago we started the program to encourage doctors to work in the specialty field of cystic fibrosis. Dr. Lumeng is one of the doctors who oversees this program.Dr. Lumeng is the Frederick G.L. Huetwell Professor for the Cure and Prevention of Birth Defects and Professor in Pediatrics and Molecular and Integrative Physiology. Dr. Lumeng is the Division Chief of Pediatric Pulmonology at the C.S. Mott Children's Hospital and Associate Director of the Michigan MSTP Program.He grew up in Indiana and graduated from Princeton University in Molecular Biology. He received his PhD in Human Genetics and MD from the University of Michigan and completed residency training in Pediatrics in the Boston Combined Pediatrics Residency Program at Boston Children's Hospital and Boston Medical Center. He then completed fellowship training in Pediatric Pulmonology at the University of Michigan and started as faculty in 2006. He runs a research lab focused on the health effects of obesity and the links between metabolism and lung health. The laboratory participates in both basic science and translational research projects in adult and pediatric obesity. He is funded by the NIH and the CF Foundation for new projects studying the changing causes of diabetes in people with CF.To contact the CF pediatric department (the Bonnell girls are pictured on this page): https://www.mottchildren.org/conditions-treatments/cystic-fibrosis-pediatric?pk_vid=6ff46bd2d38fe04c1739891353f5b28b Please like, subscribe, and comment on our podcasts!Please consider making a donation: https://thebonnellfoundation.org/donate/The Bonnell Foundation website:https://thebonnellfoundation.orgEmail us at: thebonnellfoundation@gmail.com Watch our podcasts on YouTube: https://www.youtube.com/@laurabonnell1136/featuredThanks to our sponsors:Vertex: https://www.vrtx.comViatris: https://www.viatris.com/en
This episode originally aired on October 1st, 2024. Dr. Rachel Quaney chats with Dr. Michael Keller and Dr. Burton Lee on their paper "Impact of Longitudinal Mechanical Ventilation Curriculum on Decay of Knowledge."
Antimicrobial resistance is a rising global threat. When these become ineffective, infections can become difficult or impossible to treat, leading to an increase in the spread and severity of disease. In a new study, published in Nature Medicine, a team of researchers at the Center for Phage Biology and Therapy at Yale discovered a novel approach that may revolutionize the fight against antimicrobial resistance. In the study, the research team investigated the use of phage therapy—the use of viruses, or phages, to target and kill bacteria—to help patients with cystic fibrosis, a disease in which antimicrobial resistance is a significant issue. The team pioneered a strategy to select phages that not only kill bacteria that cause infections but also weaken surviving bacteria to become less virulent or less resistant to antibiotics. Joining me today to discuss phage therapy and their research is Jon Koff, MD, Dr. Koff is an associate professor in Yale School of Medicine's Section of Pulmonary, Critical Care, and Sleep Medicine and medical director of the Center for Phage Biology and Therapy. Check out the paper: Phage Therapy May Treat Drug Resistance in Patients With Cystic Fibrosis, Study Finds Watch the video version at Outbreak News TV
Seth Hall, MBA, RRT, takes listeners on a journey through the past, present, and future of inhaled therapies. Discover how these treatments have evolved, the life-changing benefits they offer, and the revolutionary technologies that could redefine outcomes for PAH and PH-ILD patients. This Special Edition episode is sponsored by Liquidia. Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com Like, Subscribe and Follow us: www.phawarepodcast.com. #phawareMD #PHILD @Liquidia_Corp #PRINTTechnology
CardioNerds Critical Care Cardiology Council members Dr. Gurleen Kaur and Dr. Katie Vanchiere meet with Dr. Yash Patel, Dr. Akanksha, and Dr. Mohammed El Nayir from Trinity Health Ann Arbor. They discuss a case of pulmonary air embolism, RV failure, and cardiac arrest secondary to an ocular venous air embolism. Expert insights provided by Dr. Tanmay Swadia. Audio editing by CardioNerds Academy intern, Grace Qiu. A 36-year-old man with a history of multiple ocular surgeries, including a complex retinal detachment repair, suffered a post-vitrectomy collapse at home. He was found hypoxic, tachycardic, and hypotensive, later diagnosed with a pulmonary embolism from ocular venous air embolism leading to severe right heart failure. Despite a mild embolic burden, the cardiovascular response was profound, requiring advanced hemodynamic support, including an Impella RP device (Abiomed, Inc.). Multidisciplinary management, including fluid optimization, vasopressors and mechanical support to facilitate recovery. This case underscores the need for early recognition and individualized intervention in cases of ocular venous air embolism. US Cardiology Review is now the official journal of CardioNerds! Submit your manuscript here. CardioNerds Case Reports PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Pearls- Clear Vision, Clouded Heart: Ocular Venous Air Embolism with Pulmonary Air Embolism, RV Failure, and Cardiac Arrest Hypoxia, hypotension and tachycardia in a patient following ocular instrumentation are classic findings suggestive of pulmonary embolism from possible air embolism. The diagnosis of RV failure is based on clinical presentation, echocardiographic findings (such as McConnell's sign), and invasive hemodynamic assessment via right heart catheterization. Mechanical circulatory support can be considered as a temporary measure for patients with refractory RV failure. Central Figure: Approach to Pulmonary Embolism with Acute RV Failure Notes - Clear Vision, Clouded Heart: Ocular Venous Air Embolism with Pulmonary Air Embolism, RV Failure, and Cardiac Arrest 1. What is an Ocular Venous Air Embolism (VAE), and how can it be managed in critically ill patients? An Ocular Venous Air Embolism is defined as the entry of air into the systemic venous circulation through the ocular venous circulation, often during vitrectomy procedures. Early diagnosis is key to preventing cardiovascular collapse in cases of Ocular Venous Air Embolism (VAE). The goal is to stop further air entry. This can be done by covering the surgical site with saline-soaked dressings and checking for air entry points. Adjusting the operating table can help, especially with a reverse Trendelenburg position for lower-body procedures. The moment VAE is suspected, discontinue nitrous oxide and switch to 100% oxygen. This helps with oxygenation, speeds up nitrogen elimination, and shrinks air bubbles. Hyperbaric Oxygen Therapy can reduce bubble size and improve oxygenation, especially in cases of cerebral air embolism, when administered within 6 hours of the incident. Though delayed hyperbaric oxygen therapy can still offer benefits, the evidence is mixed. VAE increases right heart strain, so inotropic agents like dobutamine can help boost cardiac output, while norepinephrine supports ventricular function and systemic vascular resistance, but this may also worsen pulmonary resistance. Aspiration of air via multi-orifice or Swan-Ganz catheters has limited success, with success rates ranging from 6% to 16%. In contrast, the Bunegin-Albin catheter has shown more promise, with a 30-60% success rate. Catheterization for acute VAE-induced hemodynamic compromise is controversial, and there's insufficient evidence to support its ...
Listen in as Paula Henao, MD; Rohit Loomba, MD, MHSc; Cheryl Pirozzi, MD, MS; and Corinne Young, NP, FCCP, discuss their screening and monitoring strategies for patients with alpha-1 antitrypsin deficiency, including:Why early detection is key for improving patient outcomesHow to monitor through use of noninvasive imaging and biopsy per guideline recommendationsHow to coordinate patient care to provide much-needed multidisciplinary careWhat therapies in the pipeline could transform the treatment landscape for this genetic disease PresentersPaula Henao, MDAssistant Professor of MedicineDivision of Pulmonary, Allergy and Critical Care MedicinePenn State Hershey Medical CenterHershey, PennsylvaniaRohit Loomba, MD, MHScProfessor of MedicineChief, Division of Gastroenterology and HepatologyDirector, MASLD Research CenterUniversity of California, San DiegoSan Diego, CaliforniaCheryl Pirozzi, MD, MSAssociate Professor of Internal MedicineDivision of Pulmonary and Critical Care MedicineUniversity of UtahSalt Lake City, UtahCorinne Young, NP, FCCPPresident/FounderAssociation of Pulmonary Advanced Practice ProvidersColorado Springs, ColoradoLink to full program: https://bit.ly/4dgCRnq
In this episode of Critical Care Time, Dr. Joshua Boster joins Cyrus and Nick to explore how interventional pulmonary (IP) skills can be life-saving in the ICU. From managing malignant central airway obstruction with rigid bronchoscopy to navigating pleural disease, persistent air leaks, and even life-threatening hemoptysis, Dr. Boster shares practical insights from the front lines. Listeners will learn how IP tools can transform critical care decision-making and offer meaningful interventions when time and options are limited. Whether you're an intensivist, a trainee, or just IP-curious, this episode highlights procedures that not only restore patency—but restore hope. Give it a listen, leave us a review and let us know what you think! Hosted on Acast. See acast.com/privacy for more information.
Dr. Richard Channick, dives into the evolving world within pulmonary hypertension -- interstitial lung disease (PH-ILD). He sheds light on why early diagnosis matters and how new therapies are transforming care. Learn about the latest FDA-approved treatment and what's on the horizon. This Special Edition episode is sponsored by Gossamer Bio and Pulmovant. Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com Like, Subscribe and Follow us: www.phawarepodcast.com. #phawareMD #PHILD @UCLAHealth @GossamerBio #Pulmovant @accpchest #PHOCUSstudy #PROSERAStudy
In this episode with Dr. Rania Esteitie, Assistant Professor of Pulmonary and Critical Care Medicine at the University of Central Michigan, and a strong advocate for women in Pulmonary and Critical Care Medicine in Michigan and at the American Thoracic Society, we share her journey, challenges, and triumphs in a field historically dominated by men. We explore topics such as mentorship, gender equity, leadership development, and the importance of diversity, and representation in medicine. This episode can be found on Apple, Spotify, Anghami, and all podcast apps. #WomenInMedicine #CriticalCareMedicine #WomenInSTEM #MedicalLeadership #DiversityInMedicine #HealthcareHeroes #WomenInHealthcare #MentorshipInMedicine #LeadingTheWay #GenderEquity #WomenInICU #FutureOfMedicine
Video: https://mehlmanmedical.com/hy-usmle-q-1362-pulmonaryIG: https://www.instagram.com/mehlman_medical/Telegram: https://mehlmanmedical.com/subscribe/FB: https://www.facebook.com/mehlmanmedical
Arthur Robin Williams is an associate professor of clinical psychiatry at Columbia University and a research scientist at the New York State Psychiatric Institute. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. A.R. Williams. Death and Taxes — Is Alcohol the Solution? N Engl J Med 2025;392:1665-1667.
Dr. Ioana Preston explores the emerging field of pulmonary hypertension associated with interstitial lung disease (PH-ILD). She discusses the growing recognition of PH-ILD, especially after the introduction of inhaled treprostinil as a treatment, and highlights the importance of early screening and diagnosis. Dr. Preston also delves into the challenges of treating rare diseases, the evolution of research, and the hope for future therapies that could significantly improve patients' lives. This insightful conversation sheds light on a critical yet often overlooked aspect of pulmonary care, urging clinicians to stay vigilant and informed about PH-ILD's complexities. This Special Edition episode is sponsored by Liquidia. Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com Like, Subscribe and Follow us: www.phawarepodcast.com. #phawareMD #PHILD @Liquidia_Corp @LaheyHospital
Dr. Raj Parikh from Hartford Hospital discusses the development of the PH-ILD Detection tool, a screening tool designed to help detect pulmonary hypertension (PH) in patients with interstitial lung disease (ILD) at an early stage. Early detection is critical, as there is often a significant delay in diagnosis of PH in ILD patients, leading to worsened outcomes. This Special Edition episode is sponsored by Liquidia. Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com Like, Subscribe and Follow us: www.phawarepodcast.com. #phawareMD @HartfordHealthC @Liquidia_Corp @teamphhope #PHILD
Patricia Zettler is a professor of law at The Ohio State University Moritz College of Law. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. P.J. Zettler, T.L. Wagener, and M.L. Berman. What's Next for Nicotine? The Coming Legal and Political Battles over an FDA Proposal. N Engl J Med 2025;392:1461-1463.
Dr. Ron Zolty delves into groundbreaking advancements in treating pulmonary arterial hypertension. From the historical use of vasodilators to the revolutionary promise of sotatercept and seralutinib, Dr. Zolty unpacks how science is moving closer to halting—and possibly even reversing—PAH. This Special Edition episode is sponsored by Gossamer Bio. Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com Like, Subscribe and Follow us: www.phawarepodcast.com. #phawareMD @UNMCCOM @NebraskaMed @GossamerBio #clinicaltrial #PROSERA
Ever wake up feeling exhausted despite a full night in bed? You're not alone. In this eye-opening conversation, sleep specialist Dr. Bajoi John reveals why quality sleep might be your most underutilized superpower.Drawing from his experience treating over 50,000 patients, Dr. John dismantles the myth that sleeping less equals achieving more. "You can do more by sleeping more," he explains, challenging our hustle-focused culture with scientific evidence about how proper rest enhances every aspect of our lives.The discussion explores Dr. John's practical SLEEP-NOW method—a comprehensive framework anyone can implement tonight. From creating the perfect bedroom environment (65-70°F, dark, and electronics-free) to mental techniques that quiet racing thoughts, each strategy addresses common barriers to restorative sleep.Whether you're struggling with persistent insomnia or simply want to optimize your sleep quality, this conversation offers actionable wisdom to transform your nights and, consequently, your days. Ready to harness your sleep superpower? This episode is your comprehensive guide.Bio Dr. Bijoy John, a board-certified physician with over 25 years of experience in Pulmonary, Critical Care, and Sleep Medicine, is a leading sleep specialist based in Nashville, TN. As the founder and medical director of Sleep Wellness Clinics of America, he provides both in-person and virtual consultations, using cutting-edge diagnostics, home testing, and comprehensive treatment plans for children and adults with a wide range of sleep disorders.He is also the founder of Sleep Fix Academy, an online platform offering courses, podcasts, and resources designed to help individuals improve their sleep quality naturally and effectively.In addition to is clinical work, Dr. John serves as an Affiliate Assistant Professor at the University of Tennessee Health Science Center College of Medicine. He is a respected member of the American Academy of Chest Physicians, the American Medical Association, and the American Academy of Sleep Medicine.Dr. John has been widely recognized for his expertise, including being named one of the Top 100 Physicians in Nashville by My Nashville magazine in 2022 and receiving the Top Sleep Specialist award from Nashville Lifestyles magazine for six consecutive years. Most recently, he was featured in Marquis Who's Who as one of the Top Sleep Physicians for 2023–2024.Social Media and Website https://sleepfixacademy.com/https://www.facebook.com/sleepfixacademy/https://www.instagram.com/dr.sleepfix/https://www.linkedin.com/in/dr-sleepfix/We hope you have enjoyed this episode. Please like, comment, subscribe, and share the podcast.To find out more about Lynnis and what is going on in the V.I.B.E. Living World please go to https://link.tr.ee/LynnisJoin the V.I.B.E. Wellness Woman Network, where active participation fuels the collective journey toward health and vitality. Subscribe, engage, and embark on this adventure toward proactive well-being together. Go to https://www.vibewellnesswomannetwork.com to join. We have wonderful events, courses, challenges, guides, blogs and more all designed for the midlife woman who wants to keep her V.I.B.E. and remain Vibrant, Intuitive, Beautiful, and Empowered after 40+. Interested in an AI platform that meets all your needs? Click here
For decades, researchers have sought better treatments for pulmonary hypertension in interstitial lung disease, a condition that drastically impacts patients' quality of life. In this episode, Dr. Rajan Saggar dives into the latest advancements, including new inhaled medications, upcoming clinical trials, and the push for more personalized treatment approaches. This Special Edition episode is sponsored by Gossamer Bio and Pulmovant. Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com Like, Subscribe and Follow us: www.phawarepodcast.com. #phawareMD #PHILD @UCLAHealth @GossamerBio @Pulmovant #PROSERAstudy #clinicaltrial #PHOCUSstudy
Welcome to our second episode of the Early Clinical Learners Series - a series dedicated towards fostering clinical reasoning skills and strategies in early clinical learners! In this episode, hosts Caroline Wang, Dr. Kevin Grudzinski, and Samantha Shih guide M1 students Kenny Pham and Naomi Bennett through a classic Alert and Oriented case discussing a farmer's cough. Next, our hosts share clinical pearls and strategies regarding pulmonary diagnostic workups and pulmonary function tests. Hosts: Caroline Wang, Dr. Kevin Grudzinski, Samantha ShihGuests: Kenny Pham, Naomi BennettProduced By: Caroline WangAlert & Oriented is a medical student-run clinical reasoning podcast dedicated to providing a unique platform for early learners to practice their skills as a team in real time. Through our podcast, we strive to foster a learning environment where medical students can engage with one another, share knowledge, and gain valuable experience in clinical reasoning. We aim to provide a comprehensive and supportive platform for early learners to develop their clinical reasoning skills, build confidence in their craft, and become the best clinicians they can be.Follow the team on Twitter:A&OA fantastic resource, by learners, for learners in Internal Medicine, Family Medicine, Pediatrics, Primary Care, Emergency Medicine, and Hospital Medicine.
Eric Austin, MD, MSCI discusses early detection among people who are at risk of pulmonary arterial hypertension (PAH), particularly those who would have genetic susceptibility, or who may have congenital heart disease, or who may have connective tissue disease or other features that would make them more at risk of developing pulmonary arterial hypertension than the rest of the population. Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Follow us on social @phaware Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com #phawareMD @VUMCDiscoveries @pphnet @VUMCchildren
Targeted, image-guided interventions can make a big difference for patients with hereditary hemorrhagic telangiectasia (HHT). Learn how in this week's BackTable episode featuring Dr. Clifford R. Weiss (Director of the Johns Hopkins Vascular Anomalies Center and HHT Center of Excellence) and host Dr. Michael Barraza. --- SYNPOSIS Dr. Weiss delves into the complexities and multisystem nature of HHT, emphasizing the significance of early diagnosis and multidisciplinary care. He goes on to explain the clinical criteria for diagnosing HHT, the role of genetic and imaging screenings, and the evolving approaches to treating pulmonary arteriovenous malformations (AVMs) in adults and children. The doctors discuss the potential impact of anti-angiogenic medications on the future management of HHT. The episode closes with a nod to the pivotal role that HHT Centers of Excellence play, and the ongoing dedication to improving patient outcomes through collaborative care and innovative research. --- TIMESTAMPS 00:00 - Introduction 03:57 - Diagnosing and Screening for Hereditary Hemorrhagic Telangiectasia (HHT) 07:37 - Treatment Approaches for HHT 12:12 - Embolization Techniques and Safety Measures 19:02 - Future of HHT Treatment and Research 22:30 - Conclusion and Final Thoughts --- RESOURCES The Johns Hopkins Hereditary Hemorrhagic Telangiectasia (HHT) Center of Excellence: https://www.hopkinsmedicine.org/interventional-radiology/hht
In this episode, we review the high-yield topic Massive Hemothorax from the Pulmonary section at Medbullets.comFollowMedbullets on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbulletsLinkedin: https://www.linkedin.com/company/medbullets
© 2020-2025 Ivy Podcast Discovery LLC
